KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) Non-Current Receivables (2022 - 2025)

TherapeuticsMD (TXMD) has disclosed Non-Current Receivables for 4 consecutive years, with $14.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Receivables fell 14.09% year-over-year to $14.3 million, compared with a TTM value of $14.3 million through Sep 2025, down 14.09%, and an annual FY2024 reading of $16.0 million, down 13.38% over the prior year.
  • Non-Current Receivables was $14.3 million for Q3 2025 at TherapeuticsMD, down from $14.8 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $20.3 million in Q1 2023 and bottomed at $14.3 million in Q3 2025.
  • Average Non-Current Receivables over 4 years is $17.3 million, with a median of $17.2 million recorded in 2024.
  • The sharpest move saw Non-Current Receivables dropped 8.73% in 2023, then fell 14.09% in 2025.
  • Year by year, Non-Current Receivables stood at $20.3 million in 2022, then fell by 8.73% to $18.5 million in 2023, then decreased by 13.38% to $16.0 million in 2024, then fell by 10.87% to $14.3 million in 2025.
  • Business Quant data shows Non-Current Receivables for TXMD at $14.3 million in Q3 2025, $14.8 million in Q2 2025, and $15.4 million in Q1 2025.